Novel Mechanistic Approaches in Prevention, Treatment and Non-Invasive Assessment of Radiation Cystitis in Mice

预防、治疗和非侵入性评估小鼠放射性膀胱炎的新机制方法

基本信息

项目摘要

ABSTRACT Pelvic organ tumors in men and women are projected to account for 40% and 18%, respectively, of new cancers diagnosed, and 31% and 26%, respectively, of cancer related deaths in the United States in 2020, according to the American Cancer Society’s Cancer Facts & Figures 2020. While nearly half of all pelvic cancer patients receive radiation therapy, the dose is limited and fractionated over weeks due to the potential for developing radiation cystitis. This is a debilitating secondary condition that can lead to disruption of the urothelium, inflammation, neurogenic detrusor overactivity (NDO), hemorrhagic cystitis and chronic fibrosis that may require a cystectomy. Current therapies such as cystoscopic fulguration, intravesical formalin and hyperbaric oxygen are often ineffective and focus on restricting hemorrhage rather than urological consequences. Thus, there is a critical need for preclinical models to better understand the pathophysiology of radiation cystitis, design novel mechanistic approaches in its prevention and treatment and non-invasive monitoring of these outcomes using clinically viable imaging methods. In our mouse models, bladders are either externalized or instilled with an infrared dye for selective irradiation (10Gy; 1Gy=100rad) to cause radiation cystitis with an acute phase (1- 3days) characterized by urothelial cell (UC) apoptosis and disruption of barrier function, and a chronic phase (8wks) with inflammation, afferent sensitization, NDO, and eventually collagen deposition, fibrosis and decreased bladder wall compliance. We propose to test mechanistically different classes of therapeutic and contrast agents for which we have strong preliminary data: 1) Mitochondrial targeted free radical scavenger, XJB-5-131, to decrease reactive oxygen species that inhibit mitophagy; 2) p75 neurotrophin receptor (p75NTR) modulator, LM11A-31, to decrease urothelial cell apoptosis and barrier disruption; 3) soluble guanylyl cyclase (sGC) activator, cinaciguat, to decrease inflammation, afferent sensitization and collagen deposition to treat NDO and fibrosis; and 4) intravesical infrared dye and novel contrast media mixture, gadobutrol/ferumoxytol, to selectively irradiate the bladder within the abdomen and to enhance the capabilities of magnetic resonance imaging (MRI) for non-invasive assessment of fibrosis in the bladder wall, respectively. As LM11A-31 and cinaciguat have passed phase 1 clinical safety trials for non-urological pathologies, they have considerable clinical relevance in the prevention and treatment of radiation cystitis. The overall goals of the proposal are to better characterize the pathophysiology of radiation cystitis and to design clinically relevant treatment protocols utilizing the proposed agents individually or in combination. Progress toward this goal will be monitored using decerebrate or awake (telemetric) cystometrogram (CMG) recordings, MRI, histological and molecular approaches, mitophagy reporter (mt-keima) mice, and conditional knockout mice for NADPH cytochrome b5 reductase 3 (CyB5R3) in smooth muscle or nerves which renders sGC unresponsive to NO• in these cells.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anthony John Kanai其他文献

Anthony John Kanai的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anthony John Kanai', 18)}}的其他基金

Nitric Oxide-Soluble Guanylate Cyclase Pathway as a Target for Male Bladder Outlet Obstruction and Lower Urinary Tract Symptoms in Aging
一氧化氮可溶性鸟苷酸环化酶途径作为男性膀胱出口梗阻和衰老过程中下尿路症状的靶标
  • 批准号:
    10733864
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
Novel Mechanistic Approaches in Prevention, Treatment and Non-Invasive Assessment of Radiation Cystitis in Mice
预防、治疗和非侵入性评估小鼠放射性膀胱炎的新机制方法
  • 批准号:
    10209635
  • 财政年份:
    2021
  • 资助金额:
    $ 44.14万
  • 项目类别:
Novel Mechanistic Approaches in Prevention, Treatment and Non-Invasive Assessment of Radiation Cystitis in Mice
预防、治疗和非侵入性评估小鼠放射性膀胱炎的新机制方法
  • 批准号:
    10405017
  • 财政年份:
    2021
  • 资助金额:
    $ 44.14万
  • 项目类别:
Role of NGF signaling in the bladder after spinal cord injury
NGF信号在脊髓损伤后膀胱中的作用
  • 批准号:
    9095711
  • 财政年份:
    2015
  • 资助金额:
    $ 44.14万
  • 项目类别:
Mechanisms/Treatments of Lower Urinary Tract Dysfunction After Spinal Cord Injury
脊髓损伤后下尿路功能障碍的机制/治疗
  • 批准号:
    8415613
  • 财政年份:
    2013
  • 资助金额:
    $ 44.14万
  • 项目类别:
Mechanisms/Treatments of Lower Urinary Tract Dysfunction After Spinal Cord Injury
脊髓损伤后下尿路功能障碍的机制/治疗
  • 批准号:
    9319726
  • 财政年份:
    2013
  • 资助金额:
    $ 44.14万
  • 项目类别:
Mechanisms/Treatments of Lower Urinary Tract Dysfunction After Spinal Cord Injury
脊髓损伤后下尿路功能障碍的机制/治疗
  • 批准号:
    8723172
  • 财政年份:
    2013
  • 资助金额:
    $ 44.14万
  • 项目类别:
Mechanisms/Treatments of Lower Urinary Tract Dysfunction After Spinal Cord Injury
脊髓损伤后下尿路功能障碍的机制/治疗
  • 批准号:
    8919880
  • 财政年份:
    2013
  • 资助金额:
    $ 44.14万
  • 项目类别:
Roles of Nitric Oxide and Superoxide in Cystitis
一氧化氮和超氧化物在膀胱炎中的作用
  • 批准号:
    6913876
  • 财政年份:
    2005
  • 资助金额:
    $ 44.14万
  • 项目类别:
Roles of Nitric Oxide and Superoxide in Cystitis
一氧化氮和超氧化物在膀胱炎中的作用
  • 批准号:
    9043860
  • 财政年份:
    2005
  • 资助金额:
    $ 44.14万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了